Since ALK fusion is a important oncogenic driver fusion in NSCLC, we tested the antitumor effects of iruplinalkib and other TKIs on different xenograft models with different fusion types of ALK kinase. The gene discussed is ALK; the disease is non-small cell lung carcinoma.